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BACKGROUND: Human immunodeficiency virus–infected individuals (HIVIIs) have a higher incidence of head and neck squamous cell
carcinoma (HNSCC), and clinical and histopathological differences have been observed in their tumors in comparison with those of
HNSCC patients without a human immunodeficiency virus (HIV) infection. The reasons for these differences are not clear, and molecu-
lar differences between HIV-related HNSCC and non–HIV-related HNSCC may exist. This study compared the mutational patterns of
HIV-related HNSCC and non–HIV-related HNSCC. METHODS: The DNA of 20 samples of HIV-related HNSCCs and 32 samples of non–
HIV-related HNSCCs was sequenced. DNA libraries covering exons of 18 genes frequently mutated in HNSCC (AJUBA, CASP8, CCND1,
CDKN2A, EGFR, FAT1, FBXW7, HLA-A, HRAS, KEAP1, NFE2L2, NOTCH1, NOTCH2, NSD1, PIK3CA, TGFBR2, TP53, and TP63) were pre-
pared and sequenced on an Ion Personal Genome Machine sequencer. DNA sequencing data were analyzed with Ion Reporter soft-
ware. The human papillomavirus (HPV) status of the tumor samples was assessed with in situ hybridization, the MassARRAY HPV
multiplex polymerase chain reaction assay, and p16 immunostaining. Mutation calls were compared among the studied groups.
RESULTS: HIV-related HNSCC revealed a distinct pattern of mutations in comparison with non–HIV-related HNSCC. TP53 mutation
frequencies were significantly lower in HIV-related HNSCC. Mutations in HIV1 patients tended to be TpC>T nucleotide changes for all
mutated genes but especially for TP53. CONCLUSIONS: HNSCC in HIVIIs presents a distinct pattern of genetic mutations, particularly
in the TP53 gene. HIV-related HNSCC may have a distinct biology, and an effect of the HIV virus on the pathogenesis of these tumors
should not be ruled out. Cancer 2018;124:84-94. VC 2017 American Cancer Society.
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INTRODUCTION
Human immunodeficiency virus–infected individuals
(HIVIIs) have a higher cancer incidence than the general
population. Kaposi sarcoma and non-Hodgkin lymphoma
are the most common neoplasms among HIVIIs and are
AIDS-defining malignancies. However, since the advent of
antiretroviral therapy, the incidence of other malignant
tumors (non–AIDS-defining cancer) has increased, and they
have become important causes of death for these patients.1-4
Three factors are considered important for the ele-
vated cancer incidence among HIVIIs: high smoking rates,
immunosuppression, and increased susceptibility to infec-
tion by oncoviruses. Smoking is the main preventable cause
of cancer but is a common habit among HIVIIs. The prev-
alence of tobacco smoke exposure is 2 times higher in this
group versus the overall population.5,6 Immunosuppression
is the main characteristic of human immunodeficiency
virus (HIV) infection, and it is considered to be an impor-
tant cause of cancer development. Organ transplant
patients on immunosuppressive regimens demonstrate an
increased incidence of malignant tumors in comparison
with the general population. Their cancer incidence is simi-
lar to the frequency observed among HIVIIs, and this sug-
gests that immunodeficiency plays an important role in
HIVII-related carcinogenesis.1 An important common
effect of tobacco abuse and immunosuppression is an
increased susceptibility to infection by oncoviruses with the
subsequent development of virus-related carcinogenesis.7-10
Virus-related tumors are almost 10 times more frequent in
HIVIIs versus the general US population.11 Human her-
pesviruses and human papillomaviruses (HPVs) are respon-
sible for the majority of these cases, and they lead to the
development of not only sarcomas and lymphomas but
also squamous cell carcinomas in the anogenital and head
and neck regions.11 Although human herpesviruses are
related to AIDS-defining malignancies, HPVs are the
major oncoviruses linked to non–AIDS-defining cancers.7
All these elements are also recognized as important
risk factors for head and neck squamous cell carcinoma
(HNSCC) development and may explain the higher inci-
dence of these tumors among HIVIIs.1,2,4,12-14 HNSCC
is diagnosed at an earlier age and at a more advanced stage
in HIVIIs,15 and these tumors tend to be more aggres-
sive16 and related to worse survival rates when they express
high levels of TP53 in comparison with non-HIVIIs.17
The efficacy of current treatment approaches to HIVII-
related HNSCC is still a matter of debate.18 Radiotherapy
treatment has been found to be less effective for the con-
trol of tumor relapse and related to worse overall survival
and more treatment-related toxicity in HIVIIs.18
Whether these differences in presentation and prog-
nosis are related to the systemic effects of HIV-mediated
immunosuppression or by particular biological character-
istics of the primary tumor is still unclear.
Histopathological findings indicate that HIV-related
HNSCC has unique features such as the enrichment of
multinucleated giant tumor cells and the expression of
HIV-related protein in some tumor cells.19 These observa-
tions indicate unique pathological processes that are associ-
ated with these tumors. To better understand the behavior
of HIV-related HNSCC and possibly develop personalized
treatment approaches, it is important to determine whether
this represents a distinct molecular entity.
Recently, integrated genomic studies in HNSCC
have dramatically expanded our knowledge about the
pathogenesis, progression, and treatment of this tumor
type. For instance, these studies have revealed the genes
and pathways most frequently affected in HNSCC and
have identified HPV-related HNSCC as a distinct molec-
ular entity.20-23 In this way, we believe that a genomic
analysis of HIV-related HNSCC might reveal whether
this group of tumors has a distinct pattern of DNA altera-
tions that could indicate differences in their pathogenesis
and progression. To accomplish this, we compared the
pattern of mutations between HIV-related HNSCC and
non–HIV-related HNSCC by sequencing a panel of
genes frequently mutated in head and neck cancer.
MATERIALS AND METHODS
Patient Selection
The cohort of patients used in this study was obtained from
the Head and Neck Cancer Specialized Program of
Research Excellence Human Immunodeficiency Virus
Supplement Consortium. IRB approval or exemption to
share deidentified data with the study data center was
obtained from sample collection sites. A detailed description
of the patient recruitment, sample collection, and clinico-
pathologic data collection has been provided in a previous
publication.17 Briefly, formalin-fixed, paraffin-embedded
(FFPE) tissue from patients diagnosed with HNSCC and
an HIV infection were retrieved after a retrospective review
of medical records. HNSCC patients not infected by HIV
were also retrieved as an age-, subsite-, and stage-matched
control group. DNA was extracted from the FFPE tissues,
and only samples with sufficient DNA yields for sequencing
were included in this study.
HPV Testing
For the HPV status classification, we considered p16
expression with immunohistochemistry and HPV
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detection with in situ hybridization (ISH) and the Mas-
sARRAY multiplex polymerase chain reaction (PCR)
assay. A detailed description of these methods can be
found in Walline et al’s work.17 Briefly, p16 expression
(CINtec; mtm Laboratories) was evaluated semiquantita-
tively on the basis of the expression intensity ([1] no stain-
ing, [2] low intensity, [3] moderate intensity, or [4] high
intensity) and the proportion of positive cells ([1] <5%,
[2] 5%-20%, [3] 21%-50%, or [4] 51%-100%). The p16
expression score was determined as the product of the
intensity and the proportion of p161 cells. Scores of 1 to
4 were considered negative/low, scores of 5 to 11 were
considered moderate, and scores of 12 to 16 were consid-
ered high.17
HPV detection based on ISH was performed with
the Inform HPV III assay (Ventana Medical Systems).
This assay allows the detection of 12 oncogenic HPV
types (HPV-16, HPV-18, HPV-31, HPV-33, HPV-35,
HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-
58, and HPV-66) but does not specify the HPV type.17
DNA extracted from tumors was used for PCR-
based HPV detection with the MassARRAY HPV multi-
plex PCR assay, which was designed to detect 15 onco-
genic HPV types (HPV-16, HPV-18, HPV-31, HPV-33,
HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-
56, HPV-58, HPV-59, HPV-66, HPV-68, and HPV-
73). Samples that had p16 expression scores higher than 5
and were positive according to ISH- or PCR-based HPV
detection methods were considered HPV1. Tumors for
which HPV was detected in the absence of p16 overex-
pression were considered HPV–.
Library Preparation and DNA Sequencing
Ten nanograms of DNA was used as the input for the tar-
get DNA library preparation with the Ion AmpliSeq
Library Kit. For the amplification of the targeted DNA,
we used a customized pool of primers designed for the
amplification of all exon regions of the following genes:
AJUBA, CASP8, CCND1, CDKN2A, EGFR, FAT1,
FBXW7, HLA-A, HRAS, KEAP1, NFE2L2, NOTCH1,
NOTCH2, NSD1, PIK3CA, TGFBR2, TP53, and TP63.
The target DNA libraries were sequenced with the Ion
Personal Genome Machine sequencer platform. Variant
calls were made on the Ion Reporter server with the
AmpliSeq tumor-normal pair comprehensive cancer panel
pipeline with customized filters. Although HLA-A is
included in the sequencing assay, it is currently excluded
from the analysis because of the difficulty in accurately
calling mutations in this highly polymorphic gene.
TP53 Mutation Classification
TP53 gene mutations were classified according to 2
functional-impact and risk-classification systems proposed
by Poeta et al24 and Neskey et al.25 With Poeta et al’s sys-
tem, the TP53 mutations were classified as disruptive and
nondisruptive mutations. Disruptive mutations were those
inducing a disruption of p53 protein production (nonsense,
frameshift, in-frame, and splice site mutations) or any mis-
sense mutation occurring within L2 or L3 DNA binding
domains (codons 163-195 and 236-251) and changing the
original amino acid polarity or charge category. For Neskey
et al’s classification, we used the online EAp53 server,26
which classifiesTP53mutations into high- and low-risk cat-
egories for HNSCC and determines a numeric risk score
(Evolutionary Action score - EAscore). Only missense
mutations are classifiable in this system.
Statistical Analysis
For the statistical analysis, we used IBM SPSS Statistics
(version 22) and GraphPad Prism (version 6.07) for Win-
dows. Associations between categorical variables were
determined with Fisher’s exact test. Associations between
categorical and quantitative variables were determined
with the Mann-Whitney test when categories had 2 values
and with the Kruskal-Wallis test when categories had 3 or
more values. Significant associations were considered
when the P value was lower than .05. The log-rank test
was used to determine differences among survival curves.
RESULTS
To understand the mutation frequencies and patterns in
HIV1 HNSCC, we sequenced tumor samples from 20
HIV1 HNSCC patients. We also sequenced 32 HIV–
patients as controls (Table 1). Among HIV1 cases, 11
(55%) were HPV–, and 9 (45%) were HPV1; among
HIV– cases, 6 (18.75%) were HPV1, and 26 (81.25%)
were HPV–. Sex and tissue sites did not differ among
these groups, but HIV1HPV1 patients were signifi-
cantly younger than HIV–HPV1 patients. All HIV1
patients were smokers or former smokers, and all except
one were alcohol users. No information about tobacco
and alcohol consumption was available for HIV– cases.
DNA was extracted from FFPE samples and
sequenced on a custom Ion Torrent AmpliSeq panel con-
taining 18 genes frequently altered in HNSCC. The iden-
tified mutations as well as the mutation frequencies
described for HNSCC in The Cancer Genome Atlas
(TCGA)22 are listed in Table 2, and summary oncoprints
are shown in Figure 1. Because HPV is known to alter the
mutational landscape of HNSCC, the cohort was divided
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into 4 groups for most analyses based on the HIV and
HPV status. The associations were assessed through com-
parisons of all 4 groups together and also through com-
parisons of HIV1 and HIV– groups with the same HPV
status. Overall, 84.6% of the patient tumors were found
to have at least 1 mutation in the examined genes, and the
number of patients with tumors harboring mutations was
significantly different among the 4 groups (P 5 .002).
Among the HPV1 cases, there was no difference in the
number of tumors harboring mutations when HIV1
(55.6%) andHIV– patients (66.7%) were compared. How-
ever, among the HPV– cases, the number of mutations was
higher in the HIV– group (100%) versus the HIV1 group
(81.8%; Fig. 2A). The number of patients harboring muta-
tions was significantly lower overall in the virus-related
groups (HIV1 or/and HPV1) versus the HPV– cases
from TCGA (P < .001) as well as the HIV–HPV– group
(P 5 .004). The number of genes mutated per patient and
the number of mutations per patient varied among the
groups (Fig. 2B,C). Both variables showed higher values
amongHPV– patients, regardless of the HIV status.
No mutations were detected in 4 of the studied
genes that are known to have low mutation frequencies in
HNSCC (AJUBA, CASP8, CCND1, and TGFBR2).
Mutations in the TP53 and NOTCH1 genes were
detected in all groups.When we compared the frequencies
of gene mutations among the groups, only TP53 muta-
tions were significantly different (P < .001; Table 2).
HIV–HPV– patients had the highest frequency of muta-
tions in the TP53 gene (88.5%), whereas HIV1HPV1
patients had the least number of mutations in this gene
(11.1%). A strikingly high frequency of TP53 mutations
was observed in HPV1 patients (33.3% of all 15 HPV1
cases) in comparison with other HNSCC HPV1
sequencing studies. We do not currently have an explana-
tion for this high rate. Mutations in the NFE2L2 gene
were found in 2 of 20 HIV1 patients (10%); this was a
higher frequency of detection in comparison with the fre-
quency for non-HIV patients (3.1%) and that reported
for the TCGA cohort (6.5%). NOTCH1 mutations were
observed in 3 of 9 HIV1HPV1 patients (33.3%), and
this was a higher mutation frequency in comparison with
the frequency of our other groups and that reported in
the TCGA data set. However, statistical significance was
not reached for the NFE2L2 and NOTCH1 associations.
NSD1 mutations were differentially distributed among
tumor sites (P 5 .025): they were observed in the larynx
(2 mutated cases) and other head and neck sites (1
mutated case) but were absent in oral cavity and orophar-
ynx cases. This is consistent with the distribution of
NSD1 mutations in TCGA. The frequency of mutations
in any gene did not differ significantly between HIV1
and HIV– tumors with the same HPV status.
To assess qualitative differences in TP53 mutations,
we compared the types of TP53 mutations among the
groups (Fig. 3). Although HPV1 cases exhibited only mis-
sense TP53 mutations, HPV– tumors also contained trun-
cating and in-frame indel mutations. Among HIV1HPV–
cases, truncating mutations were the most common
(66.7%), whereas these mutations represented just 26.9%
of the HIV–HPV– events. Next, we used 2 TP53
functional-impact and risk-classification systems previously
used for HNSCC (Table 3). With both systems, TP53
mutations related to aggressive tumors (high-risk and dis-
ruptive) were more prevalent in HIV– and HPV– cases.
The mutations in virus-related cases were predominantly
classified as wild-type or low-risk/nondisruptive mutations.
Truncating and frameshift mutations are not classifiable in
Neskey et al’s system25 and are, therefore, called other.
These were more prevalent in the HIV1 group (45% of
mutated cases) versus the HIV– group (30.8% of wild-type
cases).
TABLE 1. Clinical Characteristics of the Studied Head and Neck Cancer Patients
Characteristic HIV1HPV1 (n 5 9) HIV1HPV– (n 5 11) HIV–HPV1 (n 5 6) HIV–HPV– (n 5 26) Pa Pb Pc
Sex, No.
Male 8 9 6 25 .309 1.000 .205
Female 1 2 0 1
Age, mean 6 SD, y 43.8 6 10.5 52.3 6 7.07 54.6 6 7.03 54.3 6 11.3 .061 .036 .384
Tumor site, No.
Oral cavity 2 2 2 14 .188 .580 .228
Oropharynx 5 3 3 5
Larynx 0 3 1 4
Other head and neck sites 2 3 0 3
Abbreviations: HIV, human immunodeficiency virus; HPV, human papillomavirus; SD, standard deviation.
a Comparison among all 4 groups.
bComparison between HIV1 and HIV– patients with HPV1 tumors.
c Comparison between HIV1 and HIV– patients with HPV– tumors.
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We also assessed the types of nucleotide changes in
each studied group for all genes as well as the TP53 gene
individually (Fig. 4). C>Tmutations were the most prev-
alent nucleotide changes observed in all groups and for
the majority of the genes. Only the genes NFE2L2,
NSD1, and PIK3CA showed more C>G, C>A, and
T>C nucleotide changes, respectively. No significant dif-
ference in the distribution of nucleotide changes was
observed among the 4 groups (P 5 .93; Fig. 4A) or
between HIV1 and HIV– groups with the same HPV
status (P5 .24 for HPV1 tumors and P5 .98 for HPV–
tumors). No difference in the pattern of nucleotide
change distribution was observed when patients were
grouped according to their HIV status (P5 .95; Fig. 4B).
As for nucleotide changes in the TP53 gene, C>T
changes were the most commonly observed, but no sta-
tistical difference was observed among the 4 groups (P
5 .80; Fig. 4C) or between HIV1 and HIV– samples
with the same HPV status (P 5 .34 for HPV1 tumors
and P 5 .92 for HPV– tumors). Although the fre-
quency of C>T changes was higher among tumors with
an HIV infection (66.7%) versus HIV– tumors
(43.3%), the difference between them was not signifi-
cant (P 5 .95; Fig. 4D).
Considering the high frequency of C>T mutations
in these samples, we investigated the 50 flanking nucleo-
tide for each mutation (Fig. 4E). HIV1HPV– samples
exhibited a higher frequency of TpC>T mutations
Figure 2. Overall mutation pattern according to each studied group. (A) Frequencies of mutated and wild-type cases for the
studied genes (y-axis) according to each studied group. Groups with the same HPV status were compared, and a few HIV1 cases
with mutations were found with HPV– tumors. (B) Number of genes mutated per patient in each studied group. No differences in
the number of genes mutated per patient were observed between groups with the same HPV status. (C) Number of overall muta-
tions per patient in each group. No differences in the number of mutations per patient were observed between groups with the
same HPV status. HIV indicates human immunodeficiency virus; HPV, human papillomavirus.
Figure 1. Oncoprint showing the frequencies of the mutations detected in each studied group. HIV indicates human immunodefi-
ciency virus; HPV, human papillomavirus; WT, wild type.
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(26.3%) than tumors of HIV–HPV– patients (10.2%)
when all mutated genes were taken into account. As for
HPV1 tumors, TpC>T changes were observed only
among HIV1 patients (42.9% of all mutations) and were
absent among HIV– ones (P 5 .02). When tumors were
grouped according their HIV status, regardless of the
HPV infection status, the frequency of TpC>T was sig-
nificantly higher among HIV1 patients (34.8%) versus
HIV– patients (10.9%; P5 .02; Fig. 4F). The same trend
was observed when only the TP53 gene was considered:
only HIV1 tumors exhibited TpC>T nucleotide
changes (P5 .02; Fig. 4H).
Differences in 5-year survival rates were determined
for patients with respect to their HIV/HPV group, TP53
status (wild-type vs mutated), and TP53 mutation type
(insertion/deletion, transition, or transversion). No signif-
icant differences between survival curves were observed in
any comparison (P 5 .45, P 5 .30, and P 5 .46,
respectively). The presence of mutations in other genes
(alone or in combination) was also not associated with
survival in these patients. Because of the absence of TNM
information for HIV– patients, the influence of the tumor
clinical stage on these results was not able to be
determined.
DISCUSSION
In this study, we observed an overall decreased frequency
of mutations in HIV1 HNSCCs, and HIV-related
HNSCCs had a distinct pattern of genetic mutations in
the TP53 gene characterized by truncating mutations and
TpC>T nucleotide changes.
HIVIIs are a unique group of patients in the context
of HNSCC. They have greater exposure to tobacco and
alcohol, have impaired immune function, and conse-
quently are more prone to infection by high-risk HPV.4-
7,14 In this way, these patients have multiple key risk
Figure 3. Mutation maps of the TP53 gene in each studied group. Green dots represent missense mutations, red dots represent
truncating mutations, and black dots represent in-frame indels; truncating and in-frame indels were observed only among HPV–
cases. The frequency of truncating mutations was significantly higher among HIV1 cases versus HIV– patients. HIV indicates
human immunodeficiency virus; HPV, human papillomavirus.
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factors for the development of cancer and particularly
HNSCC. Not surprisingly, HIVIIs have higher rates of
HNSCC than the general population. It has been
reported that HIVIIs with HNSCC present at a more
advanced tumor stage and have reduced survival
rates.15,16,18,27 However, it is not clear whether these
TABLE 3. Association Between the TP53 Mutation Score and the Clinical Characteristics of Head and Neck
Cancer Patients
TP53 Mutation Score: Neskey et al25 TP53 Mutation Score: Poeta et al24
Characteristic WT Low Risk High Risk Othera P Pb WT Nondisruptive Disruptive P Pb
Sex, No.
Male 14 9 14 11 1.000 — 14 24 10 1.000 —
Female 1 0 1 2 — 1 2 1 —
Age, mean 6 SD, y 47.2 6 12.2 54.5 6 8.36 53.8 6 9.09 53.6 6 11.1 .419 — 47.2 6 12.2 53.6 6 10.2 54.7 6 7.53 .354 —
Tumor site, No.
Oral cavity 7 1 6 6 .119 — 7 9 4 .303 —
Oropharynx 7 3 5 1 — 7 7 2 —
Larynx 0 4 2 2 — 0 5 3 —
Other head and
neck sites
1 1 2 4 — 1 5 2 —
HIV status, No.
1 10 3 2 5 .011 — 10 6 4 .020 —
– 5 6 13 8 — 5 20 7 —
HPV status, No.
1 10 2 3 0 .001 — 10 3 2 <.001 —
– 5 7 12 13 — 5 23 9 —
Virus infection
status, No.
Present 12 5 4 5 .022 — 12 8 6 .010 —
Absent 3 4 11 8 — 3 18 5 —
HIV/HPV status, No.
1/1 8 0 1 0 .001 .071 8 1 0 .001 .071
–/1 2 2 2 0 2 2 2
1/– 2 3 1 5 .210 2 5 4 .448
–/– 3 4 11 8 3 18 5
Abbreviations: HIV, human immunodeficiency virus; HPV, human papillomavirus; SD, standard deviation; WT, wild type.
aOther refers to mutations not classifiable by Neskey et al’s system.25
b The P value was calculated through the comparison of groups with the same HPV status.
Figure 4. Distribution of nucleotide changes among the studied groups. (A) Frequency of nucleotide changes in all mutated
genes among the 4 studied groups. (B) Frequency of nucleotide changes in all mutated genes among tumors from HIV1 and
HIV– patients, regardless of the HPV status. (C) Frequency of nucleotide changes in the TP53 gene among the 4 studied groups.
(D) Frequency of nucleotide changes in the TP53 gene among tumors from HIV1 and HIV– patients, regardless of the HPV status.
(E) Frequency of each 50 nucleotide flanking C>T mutations in all mutated genes for the 4 studied groups. (F) Frequency of each
50 nucleotide flanking C>T mutations in all mutated genes among tumors from HIV1 and HIV– patients, regardless of the HPV
status. (G) Frequency of each 50 nucleotide flanking C>T mutations in the TP53 gene for the 4 studied groups. (H) Frequency of
each 50 nucleotide flanking C>T mutations in the TP53 gene among tumors from HIV1 and HIV– patients, regardless of the HPV
status. HIV indicates human immunodeficiency virus; HPV, human papillomavirus.
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findings are caused by intrinsic features of the tumor cells
or are related to host factors related to the HIV infec-
tion.22,23,28 We aimed to investigate this by comparing
the patterns of mutations in HIV-related and non–HIV-
related tumors in genes frequently mutated in HNSCC.
Because an HPV infection causes a distinct subtype of
HNSCC,22,23,28 we considered the HPV status as a key
variable as well.
Our observations regarding genetic alterations in
HNSCC from HIVIIs are unique in the literature. The
only similar analysis that we could find was performed by
Souza et al,29 who compared the patterns of TP53 muta-
tions in DNA obtained from cervical swabs (normal and
altered cytologies) from HIV-infected and uninfected
patients (all HPV1). They found that the frequencies of
TP53 mutations were similar in the 2 groups (approxi-
mately 19%).
Souza et al29 also found that the genomic position of
TP53 mutations changed with the HIV status. HIV1
patients had more mutations located in exon 7, whereas
HIV– patients had more mutations in exon 6. Our small
sample size made it difficult to compare the genomic loca-
tions of TP53mutations, but we did examine the types of
mutations. HIV1HPV– patients presented with a higher
frequency of truncating mutations, and the missense
mutations were more frequently classified as low-risk and
nondisruptive. Many TP53 mutations have been studied
for their gain-of-function properties, which can provide
novel characteristics to the tumors. Although missense
mutations in the p53 DNA binding domain can promote
a loss of DNA binding activity, this event may also change
the protein structure and lead to new potential protein
interactions, which in turn may result in p53 gain of func-
tion.30 The pattern of TP53 mutations in HIV1 cases
suggests that there are fewer gain-of-function TP53muta-
tions, and it is intriguing to speculate that this could be
related to the immune status of the individuals or HIV
itself.
Another interesting qualitative observation is the
different patterns of nucleotide changes in all mutated
genes but especially in the TP53 gene among HIV1 and
HIV– tumors. The presence of C>A changes in the TP53
gene is considered a hallmark of tobacco-related DNA
mutations in lung cancer and also in some
HNSCCs.21,22,31,32 In fact, only 1 HPV1 case in our
cohort exhibited C>A transversions. Among the
HIV1HPV– cases, the percentage of C>A changes was
similar to that among the HIV–HPV– cases (12.5% vs
9.6%), and this might be expected because all the HIV1
patients were smokers. C>T transitions have been
demonstrated as being more predominant in virally trans-
formed tumors, including HNSCC tumors.22,33 How-
ever, we demonstrated that a specific subtype of C>T
changes, the TpC>T mutations, were enriched in the
HIV-infected patients, and they conferred a virus-related
mutation fingerprint for these cases. Interestingly, the
increased number of TpC>T changes among HIV1
tumors was independent of the presence of an HPV co-
infection.
Cytosine deamination is a defense mechanism
against retrovirus infections exerted by the APOBEC fam-
ily of enzymes. Human APOBEC3G is induced by an
HIV infection to impair virus infectivity by promoting
mutations in its DNA.34-36 However, the mutagenic
potential of APOBEC3G is not restricted to the viral
genome, and cytosine deamination may also occur in
human DNA. The APOBEC-related pattern of muta-
tions, characterized by TpC>T transitions, can be
observed in numerous human cancers, including
HNSCC, and they are commonly described in the TP53
gene.37-41 Interestingly, oncogenic pathogens such as
HPV and Helicobacter pylori have been proved to cause
APOBEC3G-mediated mutations in oral and gastric epi-
thelium.37,41 The enrichment of TpC>T changes in
HIV-related tumors might suggest that HIV infection
contributes to the TP53mutation pattern observed in this
cohort.
Some studies have demonstrated that HIV-encoded
proteins may interact with the p53 protein and modulate
its function in different ways.42-44 One of these HIV-
encoded products, the Nef protein, is believed to interact
with p53 and inhibit its function and thus promote HIV
infection and replication. Greenway et al45 observed that
Nef inhibits p53-dependent apoptosis, and McLemore
et al19 found the expression of this protein in the cyto-
plasm of 7 HNSCC samples. These results might indicate
that an HIV infection would have a direct role in HNSCC
pathogenesis independent of an HPV infection.46 HIV
DNA, RNA, and viral particles have been detected in the
oral mucosa of HIVIIs,47 and it has been demonstrated
that epithelial cells from the oral mucosa lining are suscep-
tible to HIV infection.48 These findings might suggest a
direct oncogenic effect of the virus on oral epithelial cells.
More extensive sequencing would be necessary to confirm
this.
Despite the genetic differences observed among
these patients, no significant difference in survival was
observed in our analysis with respect to the HIV and HPV
status, TP53 mutation status, and TP53 mutation type.
We believe that our small sample size might limit
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definitive conclusions on the impact of such variables on
the survival of HNSCC patients. The impact of such vari-
ables should be further investigated in larger cohorts.
Considering these results, we conclude that HIV-
related HNSCC likely represents a distinct genomic
entity. The alterations observed in this study must be vali-
dated in larger cohorts, but they suggest that these tumors
in HIVIIs are biologically distinct. More studies are
needed to understand the unique etiology, pathogenesis,
and biology of these tumors and to determine whether
there are unique therapeutic modalities that would benefit
these HNSCC patients.
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